BBA
MIST icon

Baker Bros. Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Baker Bros. Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-266,667
Closed -$4.97M – 103
2019
Q3 		$4.97M Hold
266,667
– – 0.03% 63
2019
Q2 		$7.24M Buy
+266,667
New +$5.5M 0.05% 58

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baker Bros. Advisors's MIST Position: Q4 2019 in Review

Baker Bros. Advisors sold out of Milestone Pharmaceuticals (MIST) in Q4 2019, closing a stake of 266,667 shares — an estimated $4.97M sold.

Baker Bros. Advisors first reported a position in MIST in Q2 2019 and held it in 2 quarters. The position peaked at $7.24M in Q2 2019. 25 funds tracked by Wall St. Rank hold MIST as of Q4 2019.

  • Baker Bros. Advisors reported no remaining Milestone Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Baker Bros. Advisors sold 266,667 Milestone Pharmaceuticals shares in Q4 2019, an estimated $4.97M.
  • Baker Bros. Advisors first reported a position in Milestone Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Baker Bros. Advisors's Milestone Pharmaceuticals position peaked at $7.24M in Q2 2019.
  • 25 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2019.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.